Effectiveness of ginkgo diterpene lactone meglumine on cognitive function in patients with acute ischemic stroke.

OBJECTIVE

To explore the efficacy of ginkgo diterpene lactone (GDLM) on cognitive function in patients with acute ischemic stroke (AIS).

METHODS

A total of 126 patients with AIS in Shaanxi Provincial People's Hospital from July 2019 to December 2020 were collected and randomly divided into the control group and treatment group ( = 63). All patients received conventional treatment, on which 25 mg/day GDLM was administered in the treatment group. Coagulation and inflammation indexes, National Institutes of Health Stroke Scale (NIHSS) and activities of daily living scale (ADL) scores were measured before and 14 days after treatment. NIHSS and ADL scores were performed again after 3 months. Cognitive function was assessed by Montréal Cognitive Assessment (MoCA) score, Mini-Mental State Examination (MMSE) score, and potential P300.

RESULTS

After 14 days of treatment, all biochemical indices were lower than before treatment ( < 0.05). The NIHSS and ADL scores of the treatment group were significantly better than those of the control group after treatment ( < 0.05). The MoCA and MMSE scores of the treatment group improved more significantly compared with the control group ( < 0.05). After treatment, the P300 indexes of both groups were significantly better than before treatment ( < 0.05).

CONCLUSION

Conventional treatment of AIS combined with GDLM can effectively improve the cognitive function of patients, which is worthy of clinical recommendation.